Cosmetic cross-reference

Homosalate

CAS 118-56-9

Homosalate (CAS 118-56-9) is a Phase 2 pharmaceutical compound with 3 bioactivity targets and 95 adverse event associations.

SOURCE NLM DailyMed
Label records
8
SOURCE EMBL-EBI ChEMBL
Bioactivity
3
SOURCE DrugCentral
Adverse signals
95
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Homosalate
CAS Number
118-56-9
UNII
V06SV4M95S
InChIKey
WSSJONWNBBTCMG-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1377575
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL1377575 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 8 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70 HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260505
SPF 50 Dry Tropix with fragrance HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260505
SURFACE SUN SPF 50 DRY TOUCH Fragrance Free HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260505
SURFACE SUN SPF 50 DRY TOUCH Fragrance Free HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260505
SURFACE SUN SPF30 DRY TOUCH Fragrance Free HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260505
THANKYOU FARMER Sun Project Moisture Sun HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260505
THANKYOU FARMER Sun Project Soothing Sun HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260505
No 7 Prime Forever SPF 50 Primer HOMOSALATE
V06SV4M95S
 HOMOSALATE 20260430
SOURCE EMBL-EBI ChEMBL 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 38031.984615384616 nM 12 -
- AC50 669.45 nM 2 -
- IC50 19976.309999999998 nM 1 -
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Macular degeneration 263 825.896 10025409
Chronic sinusitis 94 252.53 10009137
Paraesthesia oral 98 229.979 10057372
Procedural pain 97 217.419 10064882
Vaginal flatulence 39 129.579 10064227
Body tinea 33 120.729 10005913
Female genital tract fistula 42 110.514 10061149
Radiculopathy 44 100.224 10037779
Proctitis 40 99.457 10036774
Infection susceptibility increased 33 96.407 10021866
Therapeutic product effect incomplete 127 95.668 10082200
Inhibitory drug interaction 33 93.881 10068071
Vaginal discharge 39 92.651 10046901
Drug ineffective 459 88.644 10013709
Removal of foreign body 15 87.779 10062102
Cardiac arrest 121 85.32 10007515
Dyspepsia 104 84.009 10013946
Anal inflammation 21 72.438 10050247
Glucose tolerance impaired 33 70.618 10018429
Poor quality sleep 47 70.41 10062519
Methaemoglobinaemia 28 67.626 10027496
Foetal death 35 67.41 10055690
SARS-CoV-2 test negative 18 61.07 10084273
Impaired quality of life 37 60.031 10076936
Local anaesthetic systemic toxicity 17 59.115 10082534
Bone density decreased 34 55.817 10049470
Purpura 36 54.158 10037549
Oral candidiasis 41 49.085 10030963
Product packaging confusion 15 48.718 10074776
Impaired work ability 35 47.895 10052302
Appendicolith 24 47.485 10074458
Pyrexia 240 46.845 10037660
Colitis ulcerative 44 46.717 10009900
Hyperlipidaemia 39 46.481 10062060
Constipation 138 45.436 10010774
Anaphylactic shock 41 44.48 10002199
Frequent bowel movements 39 43.234 10017367
Tracheal deviation 9 43.171 10044287
Ventricular fibrillation 38 42.809 10047290
Foreign body 17 42.664 10070245
Oral herpes 36 39.975 10067152
Proctalgia 24 39.799 10036772
Skin disorder 40 38.875 10040831
Phrenic nerve paralysis 9 37.207 10064964
Foreign body in respiratory tract 10 37.004 10079847
Accident 22 36.196 10000369
Cardiogenic shock 38 34.953 10007625
Appendicitis 27 31.539 10003011
Rheumatoid arthritis 5 30.129 10039073
Chemical burn 9 29.395 10008420

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Homosalate used for in pharmaceutical contexts?

Homosalate (CAS 118-56-9) appears in DailyMed active-ingredient label rows, including Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70, SPF 50 Dry Tropix with fragrance, SURFACE SUN SPF 50 DRY TOUCH Fragrance Free.

What are the known adverse events for Homosalate?

Homosalate has 95 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Chronic sinusitis, Paraesthesia oral, Procedural pain, Vaginal flatulence. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Homosalate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Homosalate with EU status "restricted".

What clinical phase is Homosalate in?

Homosalate is rendered with ChEMBL max phase 2.